# 2.4-2.5 Clinical Trial Phases

## 2.4 Introduction

The target is decomposed into distinct implementation phases - with appropriate decision and flexibility to allow modification as results accumulate - and discrete steps, called clinical studies, each with well defined objectives and milestones. 

Clinical trials involving new drugs/medicines are commonly classified into four phases.

<table>
  <thead>
    <tr>
      <th style="text-align:left">Phase</th>
      <th style="text-align:left">Description</th>
      <th style="text-align:left"></th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align:left">I</td>
      <td style="text-align:left">Clinical Pharmacology and Toxicity</td>
      <td style="text-align:left">First Time in Human (FTiH)</td>
    </tr>
    <tr>
      <td style="text-align:left">II</td>
      <td style="text-align:left">Initial Assessment of Efficacy</td>
      <td style="text-align:left">
        <p>Clinical Proof of Concept(PoC)</p>
        <p>Dose Ranging</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">III</td>
      <td style="text-align:left">
        <p>Full-scale Evaluation of treatment Efficacy &amp;</p>
        <p>Safety</p>
      </td>
      <td style="text-align:left">Pivotal(&#x5173;&#x952E;&#x4E8B;&#x7269;) / Confirmation</td>
    </tr>
    <tr>
      <td style="text-align:left">IV</td>
      <td style="text-align:left">Post-marketing Surveillance</td>
      <td style="text-align:left">Risk Management</td>
    </tr>
  </tbody>
</table>> By nature of the different phases, early phase \(I/II\) involve less subjects/patients but have much more procedures, visits and data collected per subjects/patients while late phases \(III/IV\) are more focused but involved more subjects/patients.--早期被试更少，但收集的信息更多。后期目标明确，需要的信息种类的变少，样本增多。  
>                                                   ![](../.gitbook/assets/image%20%287%29.png)

## 2.4.1 Phase I trials - Clinical pharmacolog \(药理学\) and toxicity

Knowledge of the relationships among Dose, Drug concentration in blood, and Clinical Response \(effectiveness and undesirable effects\) is essential to understand the use and benefit of the treatment in Human. Identification of the dose response relationship is an important issue in facilitating efficient drug development:

* Minimum/maximum effective dose **\(MED\)**
* Maximum tolerated dose **\(MTD\)**
* Dose titration scheme\(剂量滴定方案\)

<table>
  <thead>
    <tr>
      <th style="text-align:left">category</th>
      <th style="text-align:left">description</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align:left">Look at</td>
      <td style="text-align:left">
        <p>&#x2013; 1st experiment in human for new drug, schedule, or combination</p>
        <p>&#x2013; Populations selection (gender, age stratum, &#x2026;)</p>
        <p>&#x2013; Drug toxicity &amp; determine an effective dose suitable for
          subsequent Ph II</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">Typically</td>
      <td style="text-align:left">
        <p>&#x2013; Involve 20 to 100 participants (often Healthy Volunteers), often
          conducted in inpatient clinic(&#x4F4F;&#x9662;&#x8BCA;&#x6240;)
          <br />&#x1F4DA; &#x901A;&#x5E38;&#x662F;&#x7531;&#x4E00;&#x5C0F;&#x90E8;&#x5206;&#x5065;&#x5EB7;&#x7684;&#x5FD7;&#x613F;&#x8005;&#x7EC4;&#x6210;&#x3002;&#x5982;&#x679C;&#x6709;&#x75BE;&#x75C5;&#x665A;&#x671F;&#xFF08;end-stage
          disease&#xFF09;&#x4E14;&#x6CA1;&#x6709;&#x5176;&#x4ED6;&#x6CBB;&#x7597;&#x65B9;&#x5F0F;&#x7684;&#x75C5;&#x4EBA;&#x4E5F;&#x53EF;&#x4EE5;&#xFF0C;&#x6216;&#x8005;&#x8BC1;&#x636E;&#x663E;&#x793A;&#x836F;&#x7269;&#x7684;&#x836F;&#x7406;&#x5B66;(pharmacological)&#x6548;&#x5E94;&#x5728;&#x75C5;&#x4EBA;&#x548C;&#x5065;&#x5EB7;&#x5FD7;&#x613F;&#x8005;&#x6709;&#x5DEE;&#x522B;&#xFF0C;&#x6B64;&#x65F6;&#x4E5F;&#x53EF;&#x4EE5;&#x62DB;&#x52DF;&#x75C5;&#x4EBA;&#x3002;&#x8FD9;&#x79CD;&#x4F8B;&#x5916;&#x4E00;&#x822C;&#x53D1;&#x751F;&#x5728;oncology
          (&#x80BF;&#x7624;&#x5B66;) and HIV drug trials&#x3002;
          <br />&#x1F4DA; &#x5728;&#x4F4F;&#x9662;&#x8BCA;&#x6240;&#x8FDB;&#x884C;&#x65F6;&#x56E0;&#x4E3A;full-time
          staff&#x53EF;&#x4EE5;&#x89C2;&#x5BDF;&#x88AB;&#x8BD5;&#xFF0C;&#x89C2;&#x5BDF;&#x4E00;&#x822C;&#x81F3;&#x5C11;&#x6301;&#x7EED;&#x5230;&#x836F;&#x7269;&#x7684;&#x534A;&#x8870;&#x671F;&#xFF08;half-lives&#xFF09;&#x8FC7;&#x53BB;&#x4E3A;&#x6B62;</p>
        <p>&#x2013; Randomized (Double-blinded or Open Label) or not</p>
        <p>&#x2013; Dose escalation, age de-escalation studies</p>
        <p>&#x2013; Pharmacokinetic/Pharmacodynamic (PK/PD)</p>
        <p>&#x2013; The tested range of doses will usually be a fraction of the dose
          that causes harm in animal testing</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">Goal</td>
      <td style="text-align:left">Find a safe dosage: identify the Maximum Tolerated Dose (MTD) in a doseescalation
        study</td>
    </tr>
  </tbody>
</table>### Pharmacokinetic/Pharmacodynamic \(PK/PD\)Modelling

The purpose is to establish a primary evaluation of the safety and a first outline of pharmacokinetic/dynamic of the active ingredients in human.   
Pharmacokinetics\(药物代谢动力学\)may be simply defined as what the body does to the drug\(身体对药物的作用\), as opposed to pharmacodynamics\(药效学\) which may be defined as what the drug does to the body\(药物对身体的作用\).  
                                                      ![](../.gitbook/assets/image%20%2814%29.png) 

The PD process models “what the drug does to the body”, this is the called drug effect.—— PD过程模拟“药物对人体的作用”，这就是所谓的药物作用。

The PK process models “what the body does to the drug”, how the concentration is kept or eliminated by the body. ——PK过程模拟“人体对药物的作用”，人体如何保持或消除浓度，评估一种化学物的施用（administration）到身体消除（elimination）的过程。 **房室模型**（**compartmental model**）

* Liberation : Release of compound from formulation
* Absorption : Compound entering the blood circulation
* Distribution : Dispersion/Dissemination\(扩散\) of compound in the body
* Metabolism\(新陈代谢\) : Irreversible transformation of compound in child metabolites\(代谢物\)
* Excretion\(排泄\) : Removal of the compound from the body

### Single and Multiple Dose Escalation Studies

<table>
  <thead>
    <tr>
      <th style="text-align:left">Name</th>
      <th style="text-align:left">Description</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align:left">SDSS* : Single Dose Escalation Studies</td>
      <td style="text-align:left">
        <p>&#x2014;&#x2014;Conducted to model the PK/PD profile of the compound over
          time after administrating a single dose of the treatment</p>
        <p>&#x2014;&#x2014;Small groups of patients are given a single dose of the
          drug while they are observed and tested for a period of time.</p>
        <p>&#x2014;&#x2014;If they do not exhibit any adverse side effects, and the</p>
        <p>pharmacokinetic data is roughly in line with predicted safe values, the
          dose is escalated, and a new group of patients is then given a higher dose.</p>
        <p>&#x2014;&#x2014;This is continued until pre-calculated pharmacokinetic
          safety levels are reached, or intolerable side effects start showing up <b>(at which point the drug is said to have reached the Maximum tolerated dose (MTD)</b>.</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">MDSS* : Multiple Dose Escalation Studies</td>
      <td style="text-align:left">
        <p>&#x2014;&#x2014;Conducted to better understand the pharmacokinetics &amp;
          pharmacodynamics of multiple doses of the drug.</p>
        <p>&#x2014;&#x2014;A group of patients receives multiple low doses of the
          drug, whilst samples (of blood, and other fluids) are collected at various
          time points and analyzed to understand how the drug is processed within
          the body.</p>
        <p>&#x2014;&#x2014;The dose is subsequently escalated for further groups,
          up to a predetermined level.</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">Adaptive Dose finding trials</td>
      <td style="text-align:left">
        <p>&#x2014;&#x2014;Regulatory agencies and the pharmaceutical industry agree
          that inappropriate dose selection remains the major cause of late phase
          product attrition</p>
        <p>&#x2014;&#x2014;Need to improve critical decision-making in exploratory
          phase</p>
        <p>clinical development so that appropriate doses are progressed to pivotal
          studies.</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">
        <p>Adaptive dose finding studies permit more accurate</p>
        <p>determination of the effective dose to take forward to phase III studies</p>
      </td>
      <td style="text-align:left">
        <p>&#x2014;&#x2014;Increase success in pivotal trials at the same time as
          improving the efficiency of the product development process.</p>
        <p>&#x2014;&#x2014;The strategy is to initially include few patients on many
          doses to</p>
        <p>determine the dose-response, then to allocate more patients to the dose-range
          of interest, reducing the allocation of patients to &#x2018;noninformative&#x2019;
          doses.</p>
      </td>
    </tr>
  </tbody>
</table>## 2.4.2 Phase II trials - Initial Assessment of Efficacy

<table>
  <thead>
    <tr>
      <th style="text-align:left">catagory</th>
      <th style="text-align:left">description</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align:left">Look at</td>
      <td style="text-align:left">
        <p>&#x2013; Assessing the efficacy and safety of the drug and collect further
          data on optimum dose</p>
        <p>&#x2013; Look closely at the side effects in the targeted population</p>
        <p>&#x2013; Sometimes use surrogate(&#x66FF;&#x4EE3;&#x7684;) markers of
          efficacy</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">Typically</td>
      <td style="text-align:left">
        <p>&#x2013; Involve 100 to 600 subjects</p>
        <p>&#x2013; Double blind or Open-label but randomized and controlled</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">Goals</td>
      <td style="text-align:left">
        <p>&#x2013; IIa : screen out ineffective drugs&#xFF08;&#x7B5B;&#x9009;&#x51FA;&#x65E0;&#x804A;&#x836F;&#x7269;&#xFF09;</p>
        <p>&#x2013; IIb : Establsih Proof of Concept for moving to Phase III&#xFF08;&#x4E3A;&#x5411;&#x7B2C;&#x4E09;&#x9636;&#x6BB5;&#x8FC8;&#x8FDB;&#x5EFA;&#x7ACB;PoC&#xFF09;</p>
      </td>
    </tr>
  </tbody>
</table>## 2.4.3 Phase III trials - Full-scale Evaluation of treatment Efficacy

<table>
  <thead>
    <tr>
      <th style="text-align:left">catagory</th>
      <th style="text-align:left">description</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align:left">Look at indicated patient population</td>
      <td style="text-align:left">
        <p>&#x2013; To statistically confirm efficacy</p>
        <p>&#x2013; To quantify adverse events</p>
        <p>&#x2013; To complete safety requirements</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">Typically</td>
      <td style="text-align:left">
        <p>&#x2013; Involve 1000 to &gt;5000 subjects</p>
        <p>&#x2013; Highest level of blinding possible, randomized, placebo or standard
          therapy controlled</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">Goals</td>
      <td style="text-align:left">
        <p>&#x2013; IIIa : defines the &#x2018;best&#x2019; treatment, which has
          an implication of changing the current practice in treating patients</p>
        <p>&#x2013; IIIb : answers additional questions expected from or region/
          countries/population specificities</p>
      </td>
    </tr>
  </tbody>
</table>## 2.4.4 Phase IV trials - Post-marketing Surveillance

<table>
  <thead>
    <tr>
      <th style="text-align:left">catagory</th>
      <th style="text-align:left">description</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align:left">Look at</td>
      <td style="text-align:left">
        <p>&#x2013; Effectiveness</p>
        <p>&#x2013; Adverse effects</p>
        <p>&#x2013; Long-term morbidity and mortality after the treatment being used
          in a large number of patients and patients being followed up for a long
          period of time</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">Typically</td>
      <td style="text-align:left">
        <p>&#x2013; Involve &gt;5000 subjects</p>
        <p>&#x2013; Observational studies</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">Goals</td>
      <td style="text-align:left">&#x2013; Monitor Benefit-Risk balance of the medicine</td>
    </tr>
  </tbody>
</table>The Post-Marketing Surveillance is designed to detect any rare or long-term adverse drug/therapy reaction over a long-term period and a larger population than was possible prior to marketing authorization.—— 上市后监视旨在检测长期内任何罕见或长期的不良药物/疗法反应，并且比上市许可之前可能的人群更大

 Change in benefits-risks balance during Phase IV trials may result in significant SmPC changes \(e.g. restricted use\) or even withdrawal from the market——在IV期试验期间，利益风险平衡的变化可能导致SmPC发生重大变化（例如，限制使用），甚至退出市场

## 2.5 Other Typologies

### Exploratory Studies：Clear and precise objectives BUT:

* Not always lead to simple test of pre-defined hypothesis, generally **no strict control of Type I error**
* Provide the basis to define the Hypothesis for Confirmatory studies
* Could require a more flexible approach \(multiple end-points, changes inthe analyses, etc.\)
* **Cannot be** the basis of the formal proof of efficacy \(but can contribute…\) 
* Sample size must be justified, generally towards precision of estimates
* multiple objectives

### Confirmatory Studies:Adequately controlled trial with a pre-specified precise hypothesis

* To provide **EVIDENCE** of efficacy or safety
* **One Primary Objective** and a limited number of secondary objectives
* **Strict control of Type I error**
* Variables of assessment should be pre-defined, sensitive, accepted, and
* limited in number \(one primary variable\) 
* Sample size must be justified towards the hypothesis testing/decision
* criteria with strict understanding of the operational characteristics

